https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-01 / Cancer Control 2017 Apr;24(2):180-186
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-01 / Cancer Control 2017 Apr;24(2):180-1862017-04-01 00:00:002019-02-15 08:36:12Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-474
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-4742017-03-05 00:00:002019-02-15 08:47:44Immune and viral therapies for malignant primary brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-01 / Ther Adv Med Oncol 2017 May;9(5):347-368
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-01 / Ther Adv Med Oncol 2017 May;9(5):347-3682017-02-01 00:00:002017-02-01 00:00:00History and current state of immunotherapy in glioma and brain metastasis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-24 / Oncotarget 2017 Jan;8(4):7157-7174
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-24 / Oncotarget 2017 Jan;8(4):7157-71742017-01-24 00:00:002019-02-15 08:36:13Targeting immune checkpoints in malignant glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-11-01 / Immunotherapy 2016 11;8(11):1293-1308
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-11-01 / Immunotherapy 2016 11;8(11):1293-13082016-11-01 00:00:002019-02-15 08:47:27Novel vaccines for glioblastoma: clinical update and perspective
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-10-14 / J. Neurooncol. 2017 01;131(1):1-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-10-14 / J. Neurooncol. 2017 01;131(1):1-92016-10-14 00:00:002016-10-14 00:00:00Advances in immunotherapy for the treatment of glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-10-10 / Stem Cell Res Ther 2016 10;7(1):149
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-10-10 / Stem Cell Res Ther 2016 10;7(1):1492016-10-10 00:00:002019-02-15 09:00:20Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-09-29 / Cancer Immunol. Immunother. 2016 12;65(12):1499-1509
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-09-29 / Cancer Immunol. Immunother. 2016 12;65(12):1499-15092016-09-29 00:00:002019-02-15 08:47:26Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-08-10 / Expert Rev Vaccines 2017 01;16(1):27-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-08-10 / Expert Rev Vaccines 2017 01;16(1):27-362016-08-10 00:00:002019-02-15 08:47:24Advances and challenges: dendritic cell vaccination strategies for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-07 / JCI Insight 2016 Jul;1(10)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-07 / JCI Insight 2016 Jul;1(10)2016-07-07 00:00:002019-02-15 08:36:05PD-1 blockade enhances the vaccination-induced immune response in glioma
